Feeling after vaccination against the new crown
Release time:
2021-12-23
At present, the neo-crown epidemic in our country has been effectively controlled, but there are daily news reports in foreign countries that the neo-crown virus is still rampant, especially in neighboring countries such as India, Thailand and Vietnam, which is worrying. In order to prevent the domestic epidemic from rebounding, our epidemic prevention measures still cannot be relaxed.
Vaccination is a very effective epidemic prevention measure, but some people still have concerns and prejudices about the new crown vaccine. Sometimes for the general public, the data in the laboratory is not very important. Only when their relatives, friends, colleagues and neighbors have been vaccinated and nothing has happened, will they want to fight, so I hope that by sharing my own Personal experience and feelings can make more people dispel a little doubt.
I was vaccinated in the community very early. Talking about the vaccination process, it can be said that it was very smooth. The medical workers also patiently answered our various doubts. With the discovery of the new strain and the expiration of the interval between the third dose of the vaccine, there are quite a few people queuing up at the community vaccination points. After tens of minutes of long queues, we learned from the conversation that everyone was very confident about China's vaccines. After vaccination, muscle pain, some sleepy, which is the same as the common situation of other vaccines, and no other abnormalities.
Of course, although it is now advocated that everyone should take over, the country also emphasizes that there should be no one size fits all. For people who are not suitable for vaccination, medical staff will also remind everyone not to be vaccinated. It should also be reminded that the protective effect of any vaccine cannot reach 100% , and a few people may still not produce immunity or develop disease after vaccination. At present, the immune barrier of the population has not been established, so personal protective measures such as wearing masks, washing hands frequently and opening windows for ventilation are still needed after vaccination.
From my personal point of view, vaccination is first of all a kind of protection for myself. It reduces the risk of infection in public transportation and crowded places, and it is also a kind of protection for colleagues and family members. To put it further, it is also a modest contribution to the country's overall epidemic prevention and control, after all, everyone is responsible for epidemic prevention and control.
Looking at the hundreds of thousands of people killed by the epidemic abroad, I am very fortunate to be born in China, born in this peaceful and prosperous age. (Dragon Orchid)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page